EMA Authorised: Riximyo (rituximab) — Sandoz GmbH

View source ↗

Summary

EMA authorized the biosimilar Riximyo (rituximab) by Sandoz GmbH for multiple indications, including Non-Hodgkin lymphoma, rheumatoid arthritis, microscopic pol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis

Drugs mentioned

• Riximyo (rituximab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Microscopic Polyangiitis;Wegener Granulomatosis. MAH: Sandoz GmbH. Decision date: 10/07/2025